Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 27

Cat.No. Product Name Information/Activity
BCC6788 L-NMMA acetate L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively.
BCC2864 H-Arg(NO2)-OH 2149-70-4
BCC6847 TRIM 25371-96-4
BCC7881 CP 775146 702680-17-9
BCC4781 Fenofibrate Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
BCC7150 GW 7647 GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
BCC7084 Oleylethanolamide Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
BCC6828 Palmitoylethanolamide Impulsin (AM 3112) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
BCC2265 WY-14643 (Pirinixic Acid) Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
BCC2267 GW0742 GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.